CDC Panel Updates Info on Rare Side Effect After J&J Vaccine

Members of the Advisory Committee on Immunization Practices (ACIP) did not vote, but discussed and affirmed their support for recent decisions by the US Food and Drug Administration and CDC to update patient information about the very low risk of Guillain-Barré Syndrome that appears to be associated with the vaccine, but to continue offering the vaccine to people in the US.

The FDA says it has received reports of 100 cases of GBS after the Johnson and Johnson vaccine through its Vaccine Adverse Event Reporting System database through the end of June. The cases are still under investigation.

The company also presented new data suggesting that the shots generate strong immune responses against circulating variants and that antibodies generated by the vaccine stay elevated for at least 8 months.

Rates of GBS after the mRNA vaccines made by Pfizer and Moderna were around 1 case for every 1 million doses given, which is not above the rate that would be expected without vaccination.

Click here to read the complete article.